JP2024527559A5 - - Google Patents

Info

Publication number
JP2024527559A5
JP2024527559A5 JP2023581006A JP2023581006A JP2024527559A5 JP 2024527559 A5 JP2024527559 A5 JP 2024527559A5 JP 2023581006 A JP2023581006 A JP 2023581006A JP 2023581006 A JP2023581006 A JP 2023581006A JP 2024527559 A5 JP2024527559 A5 JP 2024527559A5
Authority
JP
Japan
Prior art keywords
cells
composition
enriched
population
manipulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023581006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/035884 external-priority patent/WO2023278811A1/en
Publication of JP2024527559A publication Critical patent/JP2024527559A/ja
Publication of JP2024527559A5 publication Critical patent/JP2024527559A5/ja
Pending legal-status Critical Current

Links

JP2023581006A 2021-07-01 2022-06-30 操作されたナチュラルキラー(nk)細胞及び関連する方法 Pending JP2024527559A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163217718P 2021-07-01 2021-07-01
US202163217722P 2021-07-01 2021-07-01
US202163217726P 2021-07-01 2021-07-01
US63/217,718 2021-07-01
US63/217,722 2021-07-01
US63/217,726 2021-07-01
PCT/US2022/035884 WO2023278811A1 (en) 2021-07-01 2022-06-30 Engineered natural killer (nk) cells and related methods

Publications (2)

Publication Number Publication Date
JP2024527559A JP2024527559A (ja) 2024-07-25
JP2024527559A5 true JP2024527559A5 (cg-RX-API-DMAC7.html) 2025-07-07

Family

ID=83507447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023581006A Pending JP2024527559A (ja) 2021-07-01 2022-06-30 操作されたナチュラルキラー(nk)細胞及び関連する方法

Country Status (7)

Country Link
US (1) US20240316102A1 (cg-RX-API-DMAC7.html)
EP (1) EP4362957A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527559A (cg-RX-API-DMAC7.html)
KR (1) KR20240051112A (cg-RX-API-DMAC7.html)
AU (1) AU2022301302A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225985A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023278811A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230088306A (ko) * 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(nk) 세포 조성물 및 이를 생성하는 방법
US20250375524A1 (en) * 2022-06-30 2025-12-11 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
CN116445416B (zh) * 2023-06-08 2023-10-17 山东兴瑞生物科技有限公司 一种基因修饰的car-nk细胞及其制备方法和应用
WO2024251290A1 (en) * 2023-06-09 2024-12-12 Suzhou Cure Genetics Biosciences Co., Limited Engineered immune cells and uses thereof
KR20240175366A (ko) * 2023-06-12 2024-12-20 한국화학연구원 Nk 세포의 증식 촉진 또는 활성화용 조성물 및 그의 용도
CN119613562A (zh) * 2023-09-14 2025-03-14 重庆精准生物技术有限公司 细胞因子融合蛋白及其应用
EP4777120A1 (en) * 2023-09-15 2026-07-22 Singular Immune, Inc. Composition and method of use recombinant fusion protein to generate car-immune cells
KR20260114545A (ko) * 2023-10-20 2026-07-22 에이투 바이오쎄라퓨틱스, 인크. 조작된 인터루킨 및 이의 용도
WO2025150751A1 (ko) * 2024-01-11 2025-07-17 사회복지법인 삼성생명공익재단 Nk 세포의 활성화 및 증폭용 배양보조세포 및 이의 용도
WO2025245399A1 (en) * 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells
WO2025251226A1 (en) * 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell
WO2026096885A1 (en) * 2024-11-01 2026-05-07 The Medical College Of Wisconsin, Inc. Compositions that target cd47 and cd138 and methods of making and using the same

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2002092134A1 (en) 2001-05-14 2002-11-21 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition
ES2348868T3 (es) 2002-12-13 2010-12-16 Genetix Pharmaceuticals Inc. Vectores retrovirales terapeuticos para terapia genica.
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
JP2007054069A (ja) 2005-08-24 2007-03-08 Medizinische Hochschule Hannover 自己不活性化レトロウイルスベクター
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
EP1757702A1 (en) 2005-08-24 2007-02-28 Medizinische Hochschule Hannover Self-inactivating gammaretroviral vector
EP2132322A4 (en) 2007-03-02 2013-02-20 Richmond Chemical Corp METHOD FOR INCREASING YIELD AND IMPROVING PURIFICATION OF PRODUCTS FROM REACTIONS WITH TRANSAMINASE
ES2708856T3 (es) 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales
DK2197903T3 (en) 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
EP2414524B1 (en) 2009-04-03 2017-08-23 Centre National De La Recherche Scientifique Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements
US20120164118A1 (en) 2009-05-04 2012-06-28 Fred Hutchinson Cancer Research Center Cocal vesiculovirus envelope pseudotyped retroviral vectors
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
GB201212902D0 (en) 2012-07-20 2012-09-05 Univ Singapore Combinatoric encoding methods for microarrays
WO2014121005A1 (en) 2013-02-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Retroviral vector packaging cell lines and methods of purifying and producing retroviral particles
CA2920539C (en) 2013-08-08 2024-01-02 Cytune Pharma Combined pharmaceutical composition
GB201318347D0 (en) 2013-10-16 2013-11-27 Ucl Business Plc Retroviral vectors
SG11201608701QA (en) 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
MX2018010484A (es) 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
AT519217B1 (de) 2016-10-04 2018-08-15 Carboncompetence Gmbh Vorrichtung und Verfahren zum Aufbringen einer Kohlenstoffschicht
EP3581190B1 (en) 2016-12-09 2021-03-10 ONK Therapeutics Limited Engineered natural killer cells and uses thereof
AU2018219895C1 (en) * 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
EP3634437A4 (en) 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
WO2019010384A1 (en) 2017-07-07 2019-01-10 The Broad Institute, Inc. METHODS FOR DESIGNING GUIDE SEQUENCES FOR GUIDED NUCLEASES
BR112020011017A2 (pt) 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
AU2019243315A1 (en) 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
AU2019271366B2 (en) 2018-05-16 2026-02-26 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human NK cells using Cas9 ribonucleoproteins
ES3068417T3 (en) 2018-09-13 2026-05-29 Nkarta Inc Natural killer cell compositions and immunotherapy methods for treating a liver tumor
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CN109652379B (zh) * 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
BR112021016046A2 (pt) 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia
CN114174325A (zh) * 2019-06-04 2022-03-11 恩卡尔塔公司 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
KR20220035190A (ko) 2019-07-17 2022-03-21 페이트 세러퓨틱스, 인코포레이티드 면역 효과기 세포 조작 및 이의 용도
AU2020321354A1 (en) 2019-07-31 2022-03-03 Nkarta, Inc. Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells
US20220378831A1 (en) 2019-09-25 2022-12-01 Fate Therapeutics, Inc. Multi-targeting effector cells and use thereof
CN114867485A (zh) 2019-10-31 2022-08-05 全国儿童医院研究所 Cd38敲除的原代和扩增的人nk细胞的生成
US20230272035A1 (en) 2019-12-05 2023-08-31 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy

Similar Documents

Publication Publication Date Title
JP7148580B2 (ja) 特定の組成を有する遺伝子により改変されたt細胞製剤
US20250354119A1 (en) Methods for enhancing efficacy of therapeutic immune cells
KR102883631B1 (ko) 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법
US12447178B2 (en) Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors
JP6884697B2 (ja) T細胞を刺激および拡大する組成物および方法
CA3118616A1 (en) Selection of improved tumor reactive t-cells
JP2022520871A (ja) ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖
BR112020018670A2 (pt) Receptor de antígeno quimérico de receptor alfa 2 da il-13 (il13ra2) para imunoterapia com células t específicas para tumor
CN103756964A (zh) 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法
TWI862870B (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
KR20210033941A (ko) 개선된 t-세포 요법
US20220056411A1 (en) Methods for isolating cd8+ selected t cells
CN111499766B (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
CN119193706A (zh) 一种经遗传修饰的t细胞的制备方法
US12295362B2 (en) Formulations and processes for CAR T cell drug products
HK40117796A (zh) 免疫细胞疗法
HK40112643A (en) Boosting chimeric antigen receptor cells in the blood
HK40093010A (en) Cancer therapy involving car-engineered t-cells and parvovirus h-1
HK40101944A (en) Formulations and processes for car t cell drug products
CN121045392A (zh) 新型嵌合抗原受体
HK40071084B (en) Rituximab-resistant chimeric antigen receptors and uses thereof
HK40071084A (en) Rituximab-resistant chimeric antigen receptors and uses thereof
HK40055874B (en) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use